ENDRA Life Sciences
NDRA
9 hedge funds and large institutions have $503K invested in ENDRA Life Sciences in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
21% more capital invested
Capital invested by funds: $417K → $503K (+$86.3K)
13% more funds holding
Funds holding: 8 → 9 (+1)
0.25% less ownership
Funds ownership: 7.68% → 7.43% (-0.25%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$152K |
| 2 |
CFG
Citizens Financial Group
Providence,
Rhode Island
|
+$144K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$23K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$295 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$31.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$427 |
| 3 |
CIAM
Caitong International Asset Management
Hong Kong
|
-$19 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $159K | +$152K | +29,924 | New |
|
|
CFG
2
Citizens Financial Group
Providence,
Rhode Island
| $151K | +$144K | +28,400 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $79.5K | -$31.3K | -6,168 | -29% |
|
4
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $53.9K | – | – | – |
|
|
5
Vanguard Capital Management
Malvern,
Pennsylvania
| $39.1K | +$23K | +4,523 | +161% |
|
6
Morgan Stanley
New York
| $18.9K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $362 | -$427 | -84 | -55% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $309 | +$295 | +58 | New |
|
9
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $101 | – | – | – |
|
|
CIAM
10
Caitong International Asset Management
Hong Kong
| – | -$19 | -4 | Closed |
|
NDRA Hedge Fund Activity: Q2 2026 in Review
9 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences (NDRA) for Q2 2026, worth a combined $503K — up 21% from $417K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NDRA positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $152K. The largest seller was Geode Capital Management, cutting an estimated $31.3K.
- 9 institutional investors held ENDRA Life Sciences (NDRA) as of Q2 2026, up from 8 in Q1 2026.
- Funds reported $503K of ENDRA Life Sciences stock for Q2 2026, up 21% quarter-over-quarter.
- 3 funds opened new ENDRA Life Sciences positions in Q2 2026 and 1 closed out, a net change of +2 holders.
- The largest ENDRA Life Sciences buyer in Q2 2026 was Citadel Advisors, an estimated $152K added.
- The largest ENDRA Life Sciences seller in Q2 2026 was Geode Capital Management, an estimated $31.3K sold.
Based on aggregated 13F filings for Q2 2026.